%A Böhm,Ruwen %A Cascorbi,Ingolf %D 2016 %J Frontiers in Pharmacology %C %F %G English %K Adverse drug reactions (ADR),Drug hypersensitivity reactions,Drug-induced agranulocytosis (DIA),Drug-induced liver injury (DILI),Drug-induced Severe Cutaneous Adverse Reactions (SCAR) %Q %R 10.3389/fphar.2016.00396 %W %L %M %P %7 %8 2016-October-21 %9 Review %+ Prof Ingolf Cascorbi,Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein,Kiel, Germany,cascorbi@pharmakologie.uni-kiel.de %# %! Pharmacogenetics of drug hypersensitivity %* %< %T Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions %U https://www.frontiersin.org/articles/10.3389/fphar.2016.00396 %V 7 %0 JOURNAL ARTICLE %@ 1663-9812 %X Adverse drug reactions adverse drug reaction (ADR) occur in approximately 17% of patients. Avoiding ADR is thus mandatory from both an ethical and an economic point of view. Whereas, pharmacogenetics changes of the pharmacokinetics may contribute to the explanation of some type A reactions, strong relationships of genetic markers has also been shown for drug hypersensitivity belonging to type B reactions. We present the classifications of ADR, discuss genetic influences and focus on delayed-onset hypersensitivity reactions, i.e., drug-induced liver injury, drug-induced agranulocytosis, and severe cutaneous ADR. A guidance how to read and interpret the contingency table is provided as well as an algorithm whether and how a test for a pharmacogenetic biomarker should be conducted.